# A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

> **NCT07287748** · PHASE1 · RECRUITING · sponsor: **Alpha Fusion Inc.** · enrollment: 38 (estimated)

## Conditions studied

- DTC - Differentiated Thyroid Cancer

## Interventions

- **DRUG:** [211At]NaAt

## Key facts

- **NCT ID:** NCT07287748
- **Lead sponsor:** Alpha Fusion Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287748, "A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07287748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*